196 related articles for article (PubMed ID: 21094191)
1. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy.
Thomas AM; Kapanen AI; Hare JI; Ramsay E; Edwards K; Karlsson G; Bally MB
J Control Release; 2011 Mar; 150(2):212-9. PubMed ID: 21094191
[TBL] [Abstract][Full Text] [Related]
2. Formulation and pharmacokinetics of thermosensitive stealth® liposomes encapsulating 5-Fluorouracil.
Al Sabbagh C; Tsapis N; Novell A; Calleja-Gonzalez P; Escoffre JM; Bouakaz A; Chacun H; Denis S; Vergnaud J; Gueutin C; Fattal E
Pharm Res; 2015 May; 32(5):1585-603. PubMed ID: 25416027
[TBL] [Abstract][Full Text] [Related]
3. Design and development of folate appended liposomes for enhanced delivery of 5-FU to tumor cells.
Gupta Y; Jain A; Jain P; Jain SK
J Drug Target; 2007 Apr; 15(3):231-40. PubMed ID: 17454361
[TBL] [Abstract][Full Text] [Related]
4. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
5. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
[TBL] [Abstract][Full Text] [Related]
6. Ethogel topical formulation for increasing the local bioavailability of 5-fluorouracil: a mechanistic study.
Puri R; Jain S
Anticancer Drugs; 2012 Oct; 23(9):923-34. PubMed ID: 22926258
[TBL] [Abstract][Full Text] [Related]
7. Formation and characterization of β-cyclodextrin (β-CD) - polyethyleneglycol (PEG) - polyethyleneimine (PEI) coated Fe3O4 nanoparticles for loading and releasing 5-Fluorouracil drug.
Prabha G; Raj V
Biomed Pharmacother; 2016 May; 80():173-182. PubMed ID: 27133054
[TBL] [Abstract][Full Text] [Related]
8. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
[TBL] [Abstract][Full Text] [Related]
9. Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy.
Elmeshad AN; Mortazavi SM; Mozafari MR
J Liposome Res; 2014 Mar; 24(1):1-9. PubMed ID: 23834067
[TBL] [Abstract][Full Text] [Related]
10. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
11. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines.
Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S
J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281
[TBL] [Abstract][Full Text] [Related]
12. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
13. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.
Al Asmari AK; Ullah Z; Tariq M; Fatani A
Drug Des Devel Ther; 2016; 10():205-15. PubMed ID: 26834457
[TBL] [Abstract][Full Text] [Related]
14. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
15. 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties.
Kaiser N; Kimpfler A; Massing U; Burger AM; Fiebig HH; Brandl M; Schubert R
Int J Pharm; 2003 Apr; 256(1-2):123-31. PubMed ID: 12695018
[TBL] [Abstract][Full Text] [Related]
16. Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors.
Lim HJ; Masin D; McIntosh NL; Madden TD; Bally MB
J Pharmacol Exp Ther; 2000 Jan; 292(1):337-45. PubMed ID: 10604968
[TBL] [Abstract][Full Text] [Related]
17. Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Tang WL; Tang WH; Chen WC; Diako C; Ross CF; Li SD
Mol Pharm; 2017 Jun; 14(6):1969-1979. PubMed ID: 28460165
[TBL] [Abstract][Full Text] [Related]
18. Hyaluronic acid-decorated liposomal nanoparticles for targeted delivery of 5-fluorouracil into HT-29 colorectal cancer cells.
Mansoori B; Mohammadi A; Abedi-Gaballu F; Abbaspour S; Ghasabi M; Yekta R; Shirjang S; Dehghan G; Hamblin MR; Baradaran B
J Cell Physiol; 2020 Oct; 235(10):6817-6830. PubMed ID: 31989649
[TBL] [Abstract][Full Text] [Related]
19. Development of novel 5-fluorouracil carrier erythrocyte with pharmacokinetics and potent antitumor activity in mice bearing malignant ascites.
Wang GP; Guan YS; Jin XR; Jiang SS; Lu ZJ; Wu Y; Li Y; Li M; Luo F
J Gastroenterol Hepatol; 2010 May; 25(5):985-90. PubMed ID: 20546454
[TBL] [Abstract][Full Text] [Related]
20. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]